Ryzneuta Vitalis Therapeutics

RYZNEUTA (efbemalenograstim alfa) is proposed as a treatment to prevent low neutrophil counts (a type of white blood cell) and related fevers in adults receiving chemotherapy for cancer. It is not used for people with chronic myeloid leukaemia or myelodysplastic syndromes.